Abbott Laboratories (NYSE:ABT) Stock Holdings Lowered by New England Research & Management Inc.

New England Research & Management Inc. lowered its position in shares of Abbott Laboratories (NYSE:ABT) by 21.2% in the 4th quarter, according to its most recent disclosure with the SEC. The fund owned 20,579 shares of the healthcare product maker’s stock after selling 5,531 shares during the period. Abbott Laboratories accounts for 1.2% of New England Research & Management Inc.’s portfolio, making the stock its 22nd biggest holding. New England Research & Management Inc.’s holdings in Abbott Laboratories were worth $2,328,000 at the end of the most recent reporting period.

Other institutional investors have also modified their holdings of the company. Groupama Asset Managment grew its position in shares of Abbott Laboratories by 22.2% during the third quarter. Groupama Asset Managment now owns 228,448 shares of the healthcare product maker’s stock worth $26,000 after acquiring an additional 41,557 shares during the last quarter. Future Financial Wealth Managment LLC bought a new position in shares of Abbott Laboratories during the third quarter worth about $31,000. Peterson Financial Group Inc. bought a new position in Abbott Laboratories in the 3rd quarter valued at about $32,000. Valued Wealth Advisors LLC grew its position in Abbott Laboratories by 78.4% in the 3rd quarter. Valued Wealth Advisors LLC now owns 289 shares of the healthcare product maker’s stock valued at $33,000 after buying an additional 127 shares in the last quarter. Finally, Highline Wealth Partners LLC bought a new position in Abbott Laboratories in the 3rd quarter valued at about $37,000. Institutional investors own 75.18% of the company’s stock.

Abbott Laboratories Stock Performance

ABT stock opened at $127.86 on Thursday. The company has a debt-to-equity ratio of 0.32, a quick ratio of 1.14 and a current ratio of 1.60. The stock has a market cap of $221.77 billion, a P/E ratio of 16.71, a P/E/G ratio of 2.51 and a beta of 0.73. The firm has a 50 day simple moving average of $115.71 and a 200 day simple moving average of $113.80. Abbott Laboratories has a 52 week low of $99.71 and a 52 week high of $129.85.

Abbott Laboratories (NYSE:ABT) last posted its quarterly earnings results on Wednesday, January 22nd. The healthcare product maker reported $1.34 EPS for the quarter, hitting the consensus estimate of $1.34. The business had revenue of $10.97 billion during the quarter, compared to analysts’ expectations of $11.03 billion. Abbott Laboratories had a net margin of 31.95% and a return on equity of 20.74%. The firm’s quarterly revenue was up 7.2% compared to the same quarter last year. During the same period last year, the company posted $1.19 earnings per share. Research analysts anticipate that Abbott Laboratories will post 5.15 earnings per share for the current fiscal year.

Abbott Laboratories Increases Dividend

The business also recently declared a quarterly dividend, which will be paid on Friday, February 14th. Investors of record on Wednesday, January 15th will be issued a dividend of $0.59 per share. This is a boost from Abbott Laboratories’s previous quarterly dividend of $0.55. This represents a $2.36 annualized dividend and a dividend yield of 1.85%. The ex-dividend date is Wednesday, January 15th. Abbott Laboratories’s dividend payout ratio (DPR) is currently 30.85%.

Analyst Ratings Changes

ABT has been the subject of a number of recent analyst reports. Piper Sandler increased their target price on shares of Abbott Laboratories from $131.00 to $133.00 and gave the company an “overweight” rating in a research report on Thursday, October 17th. Barclays reiterated an “overweight” rating and issued a $158.00 target price (up previously from $149.00) on shares of Abbott Laboratories in a research report on Monday. Wells Fargo & Company increased their target price on shares of Abbott Laboratories from $133.00 to $136.00 and gave the company an “overweight” rating in a research report on Thursday, January 23rd. Mizuho lifted their price objective on shares of Abbott Laboratories from $115.00 to $130.00 and gave the stock a “neutral” rating in a research note on Thursday, October 17th. Finally, UBS Group lifted their price objective on shares of Abbott Laboratories from $146.00 to $148.00 and gave the stock a “buy” rating in a research note on Thursday, January 23rd. Four research analysts have rated the stock with a hold rating and thirteen have issued a buy rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $133.06.

About Abbott Laboratories

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière’s disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon.